Liquidia Financial Ratios
NASDAQ: LQDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
27.38-0.64 (-2.28%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Liquidia ratio analysis
Liquidia earned a net margin of -43.5% in FY 2025, up from -916.6% a year earlier. Return on equity reached -154.0%, meaning Liquidia generated -1.54 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Liquidia financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Price / sales | 17.07 | 69.11 | 44.71 | 24.37 | 18.82 | 135.16 | 10.19 |
| Price / book | 60.39 | 12.19 | 16.53 | 4.29 | 3.71 | 1.41 | 2.35 |
| Gross margin | — | 58.0% | 83.5% | 82.1% | 76.5% | 67.9% | — |
| Operating margin | -32.5% | -866.6% | -419.6% | -243.3% | -263.0% | -7,989.0% | -580.1% |
| Net margin | -43.5% | -916.6% | -448.9% | -257.4% | -269.0% | -8,080.1% | -589.5% |
| Free cash flow margin | -25.3% | -702.9% | -245.0% | -183.1% | -265.6% | -7,422.2% | -621.1% |
| Return on equity (ROE) | -154.0% | -161.6% | -166.0% | -45.4% | -53.0% | -84.1% | -136.2% |
| Return on assets (ROA) | -21.0% | -55.7% | -66.3% | -31.7% | -36.9% | -60.0% | -69.1% |
| Debt / equity | — | — | — | 0.22 | 0.16 | 0.14 | 0.45 |
| Current ratio | 2.01 | 4.43 | 4.85 | 11.34 | 8.36 | 5.63 | 3.34 |
| Revenue growth | 1,031.2% | -20.0% | 9.7% | 24.0% | 1,637.8% | -90.8% | — |